News & Trends - MedTech & Diagnostics
Roche correcting blood glucose monitor defects
Healthcare professionals and consumers are advised that Roche Diabetes Care Australia, in consultation with the Therapeutic Goods Administration (TGA), is undertaking a product defect correction for Accu-Chek Guide and Accu-Chek Performa blood glucose meters.
It has been identified that Accu-Chek Guide blood glucose meters with serial numbers lower than 92911000001 and Accu-Chek Performa blood glucose meters with serial numbers between 68920000000 and 68925525056 (see image for serial number placement on the back of the meter) may:
- Display E-9 Errors (indicating that the batteries need to be replaced)
- Unexpectedly display the low battery icon
- Have short battery life
- Not power on.
If any of the above issues occur, it can lead to temporary meter unavailability that could cause a delay in therapy decisions, which in turn could lead to a serious medical issue.
The TGA Safety Advisory can be found at: https://www.tga.gov.au/alert/accu-chek-guide-and-accu-chek-performa-blood-glucose-meters
You may also like Injectable, flexible electrode could replace rigid nerve-stimulating implants
Register FREE to receive the latest news and insights from Health Industry Hub – the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
News & Trends - MedTech & Diagnostics
Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ
The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]
MoreNews & Trends - Biotechnology
AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future
AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]
MoreNews & Trends - Pharmaceuticals
Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study
Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]
More